Analysis of p53 and mdm-2 expression in 18 patients with Sézary syndrome

British Journal of Haematology

Volumn 92, Issue 4, 1996, Pages 890-899

  Marks, David I ^a   Vonderheid, Eric C ^a   Kurz, Benedikt W ^a   Bigler, Robert D ^a   Sinha, Keisha ^a   Morgan, Doris A ^a   Sukman, Abby ^a   Nowell, Peter C ^b   Haines, Dale S ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Chromosomal abnormalities; mdm 2; p53; S zary syndrome

Indexed keywords

MESSENGER RNA; PROTEIN P53; PROTEINM MDM 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHROMOSOME ABERRATION; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; SEZARY SYNDROME; T CELL LYMPHOMA; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, NORTHERN; BLOTTING, WESTERN; FEMALE; GENES, P53; HETEROZYGOTE; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SEZARY SYNDROME; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0030001775     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1996.439978.x     Document Type: Article

References (49)

1. Barak, Y. & Oren, M. (1992) Enhanced binding of a 95 Kd protein to p53 in cells undergoing p53-mediated growth arrest. EMBO Journal, 11, 2115-2121.
2. Bertness, V., Kirsch, I., Hollis, G., Johnson, B. & Bunn, P.A., Jr (1985) T-cell receptor gene rearrangements as clinical markers of human T-cell lymphomas. New England Journal of Medicine, 313, 534-538.
3. Bigler, R.D., Fisher, D.E., Wang, C.Y., Rinooy-Kan, E.A. & Kunk, H.G. (1983) Idiotype-like molecules on cells of a human T cell leukemia. Journal of Experimental Medicine, 158, 100-110.
4. Blount, P.L., Meltzer, S.J., Yin, J., Huang, Y., Krasna, M.J. & Reid, B.J. (1993) Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 90, 3221-3225.
5. Bueso-Ramos, C.E., Yang, Y., deLeon, E., McCown, P., Stass, S.A. & Albitar, M. (1993) The human MDM-2 oncogene is overexpressed in leukemias. Blood, 82, 2617-2623.
6. Bunn, P.A. Jr & Lamberg, S.I. (1979) Report of the committee on staging and classification of cutaneous T-cell lymphoma. Cancer Treatment Reports, 63, 725-728.
7. Cahilly-Snyder, L., Yang-Feng, T., Francke, U. & George, D.L. (1987) Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somatic Cellular and Molecular Genetics, 13, 235-244.
8. Chilosi, M., Doglioni, C., Menestrina, F., Montagna, L, Rigo, A., Lestani, M., Barbareschi, M., Scarpa, A., Mariuzzi, G.M. & Pizzolo, G. (1994) Abnormal expression of the p53-binding protein MDM2 in Hodgkin's disease. Blood, 84, 4295-4300.
9. Cordon-Cardo, C., Latres, E., Drobnjak, M., Oliva, M.R., Pollack, D., Woodruff, J.M., Marechal, V., Chen, J., Brennan, M.F. & Levine, A.J. (1994) Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Research, 54, 794-799.
10. Finlay, C.A. (1993) The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Molecular and Cellular Biology, 13, 301-306.
11. Haines, D.S., Landers, J.E., Engle, L.J. & George. D.L. (1994) Physical and functional interaction between wild-type p53 and mdm2 proteins. Molecular and Cellular Biology, 14, 1171-1178.
12. Harvey, M., Sands, A.T., Weiss, R.S., Heigi, M.E., Wiseman, R.W., Pantazis, P., Giovanella, B.C., Tainsky, M.A., Bradley, A. & Donehower, L.A. (1993) In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene, 8, 2457-2467.
13. Haynes, B.F., Bunn, P., Thomas, C., Eisenbarth, G.S., Minna, J. & Fauci, A.S. (1981) Cell surface differentiation antigens of the malignant T cell in Sézary syndrome and mycosis fungoides. Journal of Clinical Investigation, 67, 523-530.
14. Horio, Y., Takahashi, T., Kuroishi, S., Hibi, K., Suyama, M., Niimi, T., Shimohata, K., Yamakawa, K., Nakamura, Y., Ueda, R. & Takahashi, T. (1993) Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Research, 53, 1-4.
15. Imamura, J., Miyoshi, I. & Koeffler, H.P. (1994) p53 in hematologic malignancies. Blood, 84, 2412-2421.
16. Johnson, G.A., Dewald, G.W., Strand, W.R. & Winkelman, R.K. (1985) Chromosome studies in 17 patients with the Sézary syndrome. Cancer, 55, 2426-2433.
17. Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
18. Kuzel, T.M., Roenigk, H.H. & Rosen, S.T. (1991) Mycosis fungoides and the Sézary syndrome: a review of pathogenesis, diagnosis and therapy. Journal of Clinical Oncology, 9, 1298-1313.
19. Ladanyi, M., Cha, C., Lewis, R., Jhanwar, S.C., Huvos, A.G. & Healye, J.H. (1993) MDM2 gene amplification in metastatic osteosarcoma. Cancer Research, 53, 16-18.
20. Landers, J.E., Haines, D.S., Strauss, J.F. & George, D.L. (1994) Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene, 9, 2745-2750.
21. Lianes, P., Orlow, I., Zhang, Z.F., Oliva, M.R., Sarkis, A.S., Reuter, V.E. & Cordon-Cardo, C. (1994) Altered patterns of MDM2 and TP53 expression in human bladder cancer. Journal of the National Cancer Institute, 86, 1325-1330.
22. Livingstone, L.R., White, A., Sprouse, J., Livanos, E., Jacks, T. & Tlisty, T.D. (1992) Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 70, 923-935.
23. Lowe, S.W., Bodis, S., McClatchey, A., Remington, L., Ruley, H.E., Fisher, D.E., Housman, D.E. & Jacks, T. (1994) P53 status and the efficacy of cancer therapy in vivo. Science, 266, 807-810.
24. Lowe, S.W., Ruley, H.E., Jacks, T. & Housman, D.E. (1993) p53 dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74, 957-967.
25. Maestro, R., Gloghini, A., Doglioni, C., Gasparotto, D., Vukosavljevic, T., De Re, V., Laurino, L., Carbone, A. & Boiocchi, M. (1995) MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphoma. Blood, 85, 3239-3246.
26. Marin, M.C., Hsu, B., Meyn, R.E., Donehower, L.A., El-Naggar, A.K. & McDonnell, T.J. (1994) Evidence that p53 and bcl-2 are regulators of a common pathway important for in vivo lymphomagenesis. Oncogene, 9, 3107-3112.
27. Marks, D.I., Kurz, B.W., Link, M.P., Ng, E., Shuster, J.J., Lauer, S.J., Brodsky, I. & Haines, D.S. (1996) High incidence of potential p53 pathway inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis. Blood, 87, 1155-1161.
28. Marks, D.I., Rockman, S.P., Oziemski, M.A. & Fox, R.M. (1990) Mechanisms of lymphocytotoxicity induced by extracorporeal photochemotherapy for cutaneous T-cell lymphoma. Journal of Clinical Investigation, 86, 2080-2085.
29. Martin, H.M., Filipe, M.I., Morris, R.W., Lane, D.P. & Silvestre, F. (1992) p53 expression and prognosis in gastric carcinoma. International Journal of Cancer, 50, 859-862.
30. Momand, J., Zambetti, G.P., Olson, D., George, D.L. & Levine, A.J. (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69, 1237-1245.
31. Mosner, J. & Deppert, W. (1994) p53 and mdm2 are expressed independently during cellular proliferation. Oncogene, 9, 3321-3328.
32. Nowell, P.C., Finan, J.B. & Vonderheid, E.C. (1982) Clonal characteristics of cutaneous T cell lymphomas: cytogenetic evidence from blood, lymph nodes and skin. Journal of Investigative Dermatology, 78, 69-75.
33. Nowell, P.C., Vonderheid, E.C., Besa, E., Hoxie, J.A., Moreau, L. & Finan. J.B. (1986) The most common chromosome change in 86 chronic B cell or T cell tumors: a 14q32 translocation. Cancer Genetics and Cytogenetics, 19, 219-227.
34. Oliner, J.D., Pietenpol, J.A., Thiagalingam, S., Gyuris, J., Kinzler, K.W. & Vogelstein, B. (1993) Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature, 362, 857-860.
35. Oziemski, M.A., Rockman, M.A., Marks, D.I., Wilde, E.J., Green, M.D., Varigos, G.A. & Fox, R.M. (1991) Extracorporeal photochemotherapy in the treatment of cutaneous T-cell lymphoma. Complexity of objective evaluation. International Journal of Dermatology, 30, 814-817.
36. Prokocimer, M. & Rotter, V. (1994) Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages. Blood, 84, 2391-2411.
37. Quesnel, B., Preudhomme, C., Oscier, D., Lepelley, P., O'Hooghe, M.C., Facon, T., Zandecki, M. & Fenaux, P. (1994) Overexpression of the mdm-2 gene is found in some cases of haematological malignancies. British Journal of Haematology, 88, 415-418.
38. Sambrook, J., Fritsch, E.F. & Maniatis, T. (1989) Molecular Cloning: a Laboratory Manual, 2nd edn. Cold Spring Harbor Laboratory Press, New York.
39. Spinardi, L., Mazars, R. & Theillet, C. (1991) Protocols for an improved detection of point mutations by SSCP. Nucleic Acids Research, 19, 4009.
40. Thor, A.D., Moore, D.H., Edgerton, S.M., Kawasaki, E.S., Reihsaus, E., Lynch, H.T., Marcus, J.N., Schwarte, L., Chen, L.-C., Mayall, B.H. & Smith, H.S. (1992) Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancer. Journal of the National Cancer Institute, 84, 845-855.
41. Vogelstein, B. & Kinzler, K.W. (1992) p53 function and dysfunction. Cell, 70, 523-526.
42. Vonderheid, E.C., Bigler, R.D., Greenberg, A.S., Neukum, S.J. & Micaily, B. (1994) Extracorporeal photopheresis and recombinant interferon alfa 2b in Sézary syndrome. American Journal of Clinical Oncology, 17, 255-263.
43. Waldmann, T.A., Greene, W.C., Sarin, P.S., Saxinger, C., Blayney, D.W., Blattner, W.A., Goldman, C.K., Bongiovanni, K., Sharrow, S., Depper, J.M., Leonard, W., Uchiyama, T. & Gallo, R.C. (1984) Functional and phenotypic comparison of human T cell leukemia/ lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative Sézary leukemia, and their distinction using anti-Tac monoclonal antibody identifying the human receptor for T cell growth factor. Journal of Clinical Investigation, 73, 1711-1718.
44. Watanabe, T., Hotta, T., Ichikawa, A., Kinoshita, T., Nagai, H., Uchida, T., Murate, T. & Saito, H. (1994) The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood, 84, 3158-3165.
45. Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P. & Fenaux, P. (1994) P53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood, 84, 3148-3157.
46. Weiner, M.S., Bianco, C. & Nussenweig, V. (1973) Enhanced binding of neuraminidase treated sheep erythrocytes to human T lymphocytes. Blood, 42, 939-946.
47. Wieselthier, J.S. & Koh, H.K. (1990) Sézary syndrome: diagnosis, prognosis and critical review of treatment options. Journal of the American Academy of Dermatology, 22, 381-401.
48. Wu, X., Bayle, J.H., Olson, D. & Levine, A.J. (1993) The p53-mdm-2 autoregulatory feedback loop. Genes and Development, 7, 1126-1132.
49. Zelickson, B.D., Peters, M.S., Muller, S.A., Thibodeau, S.N., Lust, J.A., Quam, L.M. & Pittelkow, M.R. (1991) T-cell receptor gene rearrangement analysis: cutaneous T cell lymphoma, peripheral T cell lymphoma, and premalignant and benign cutaneous lymphoproliferative disorders. Journal of the American Academy of Dermatology, 25, 787-796.